Mohammed Z. Zamer

Mohammed Z. Zamer

Auto-generated profile, based on publicly available information

Mohammed Z. Zamer

Department of Medical Oncology, Mater Misericordiae University Hospital, D07 R2WY Dublin, Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DCDarren Cowzer
Darren Cowzer
MZMohammed Zameer
Mohammed Zameer
MCMichael Conroy
Michael Conroy
Walter KolchWalter Kolch
Walter Kolch
ADAustin Duffy
Austin Duffy
Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.

22 September 2026 in The Breast
Verified
Journal Article
Open access
CKCatherine Kelly
Catherine Kelly
LPLajos Pusztai
Lajos Pusztai
KBKathleen Bennett
Kathleen Bennett
SWSiun Walsh
Siun Walsh
MZMohammed Z. Zamer
Mohammed Z. Zamer
KMKeith Mulready
Keith Mulready